Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acromegaly | D000172 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Rubitecan |
INN | rubitecan |
Description | Rubitecan is a pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin. It has a role as an antineoplastic agent, an EC 5.99.1.2 (DNA topoisomerase) inhibitor and a prodrug. It is a pyranoindolizinoquinoline, a C-nitro compound, a semisynthetic derivative, a tertiary alcohol and a delta-lactone. |
Classification | Small molecule |
Drug class | antineoplastics (camptothecin derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c([N+](=O)[O-])cccc3nc2-1 |
PDB | — |
CAS-ID | 91421-42-0 |
RxCUI | — |
ChEMBL ID | CHEMBL77305 |
ChEBI ID | 90225 |
PubChem CID | 472335 |
DrugBank | — |
UNII ID | H19C446XXB (ChemIDplus, GSRS) |